All Type of News
Court approves normalized management of Yungjin Pharm
The Seoul District Court on October 4 gave the green light to the normalized operation of Yungjin Pharm.
With the court approval, the management of Yungjin, which has been under court receivership since 1997, w...
Reported ADR cases top 387 for three years, KFDA says
A total of 387 cases relating to drug adverse reaction (ADR) have been reported from related pharmaceutical firms for the past three years, according to data released by the Korea Food and Drug ...
Pharmaceutical stocks likely pick up in coming quarters
Pharmaceutical stocks will likely get a boost in the coming quarters on their defensive nature and expectations for visible outcomes of R&D new drug projects, bolstered by potential sales of generics over Novarsc and ...
Government urged to promote drug utilization review system
During the recent National Assembly's inspection of the Health and Welfare Ministry at the Government Complex in Kwachon, south of Seoul, two lawmakers of the main opposition Grand National Party questioned whether th...
Green Cross Sang-A and PBM merged under Green Cross.
Green Cross Sang-A will be renamed to Green Cross corporation in the shareholder's meeting on Oct. 4 after the merger of Green Cross PBM on Sept. 30.
Now, Green Cross Holdings will stand as a stock holding company...
Lilly Korea launches Cialis campaign
Lilly Korea said it has launched its Cialis campaign, urging patients with erectile dysfunction to take the drug before finishing their daily work.
For health care providers, pharmacists and ED patients this campai...
International conference of pharmaceutical medicine to hold in Sept. 2006
The Seoul international conference of pharmaceutical medicine (ICPM2006) will open in Seoul Korea for the first time in Asia in Sept. 2006.
Mr. Lee Dong-ho, the chief organizing commissioner of ICPM2006 took part i...
Court approves normalized management of Yungjin Pharm
The Seoul District Court on October 4 gave the green light to the normalized operation of Yungjin Pharm.
With the court approval, the management of Yungjin, which has been under court receivership since 1997, w...
Merck & Co. announces voluntary withdrawal of Vioxx from worldwide market
Merck &. Co., Inc. on September 30 announced a voluntary worldwide withdrawal of Vioxx (rofecoxib), its arthritis and acute pain medication. The company's decision, which is effective immediately, is based on new, thr...
Vioxx to be removed from market within two months
Following the September 30 announcement of Merck &. Co. to remove Vioxx (rofecoxib) from the United States and worldwide market, MSD Korea informed the Korea Food and Drug Administration of its voluntary withdrawal an...
